EP Patent

EP1789119A2 — Conversion of nitrogen dioxide (no2) to nitric oxide (no)

Assigned to Vero Biotech Inc · Expires 2007-05-30 · 19y expired

What this patent protects

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of anti…

USPTO Abstract

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

Drugs covered by this patent

Patent Metadata

Patent number
EP1789119A2
Jurisdiction
EP
Classification
—
Expires
2007-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Vero Biotech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.